JAK inhibitors and myelofibrosis, Einstein and ruxolitinib

Haematologica

Volumn 100, Issue 4, 2015, Pages 409-411

  Harrison, Claire ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUPARLISIB; EVEROLIMUS; GIVINOSTAT; GLASDEGIB; IMETELSTAT; JANUS KINASE; PANOBINOSTAT; PENTRAXIN; PRACINOSTAT; RUXOLITINIB; SONIDEGIB; VORINOSTAT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; MORTALITY; PRIMARY MYELOFIBROSIS;

HUMANS; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84926358760     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124099     Document Type: Editorial

References (30)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352 (17):1779-1790.
5. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369 (25):2379-2390.
6. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
7. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552-1555.
8. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutationsbased molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494-500.
9. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601-612.
10. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
11. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
12. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
13. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;(4):479-488.
14. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
15. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123(14):2157-2160.
16. Hagop K, Kiladjian J-J, Gotlib J, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood. 2013;122(21):abstract 2820.
17. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98(12):1872-1876.
18. Al-Ali HK, Hubert K, Lange T, et al. Complete clinical, histopathologic and molecular remission of primary myelofibrosis with long-term treatment with the JAK1/2 inhibitor ruxolitinib. 56th ASH Annual Meeting. San Fransisco, CA, USA. 6-9, 2014. Abstract 1836.
19. Galli S, McLornan D, Harrison C. Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opin Drug Saf. 2014;13(7):967-976.
20. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leukemia Res. 2013;37(2):214-220.
21. Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28(2):449-451.
22. Rudolph J, Cornez I, Brossart P, Wolf D. The JAK1/JAK2 inhibitor ruxolitinib substantially affects NK cell biology. Blood. 2013;122(21):16.
23. Wolschke C, Alchalby H, Ayuk F, et al. The Pan-JAK inhibitor ruxolitinib impairs T-cell activation, cytokine production and proliferation in vivo and in vitro. Blood. 2013;122(21):2001.
24. Campanelli R, Fois G, Poletto V, et al. Decrease of T regulatory cells in patients with myelofibrosis receiving ruxolitinib. Blood. 2013;122(21):4057.
25. Kordasti SY, Seidl T, Abellan PP, et al. JAK inhibition reduces CD25 high CD27+ FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood. 2013;122(21):4092.
26. Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol. 2012;11(8):913-918.
27. Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2014;23(1):7-11.
28. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nature Med. 2014;20(9):1043-1049.
29. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832-3842.
30. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.